Latest Merck Stories
DARMSTADT, Germany, September 12, 2014 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, announced today that its biopharmaceutical division will discontinue the clinical
- Research grants awarded for five out of more than 200 proposals, highlighting continued commitment to multiple sclerosis (MS) ROCKLAND, Mass., Sept.
-- Providing IVF clinicians objective embryo viability data and another tool to support patient outcomes MISSISSAUGA, ON, Sept.
- EMD Serono provides funding for ACP's multicenter longitudinal OPT-UP clinical study ROCKLAND and WALTHAM, Mass., Sept.
- Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of gadolinium-enhancing lesions, assessments of predictive scores for disease activity and disability progression,
BOSTON, Sept. 8, 2014 /PRNewswire/ -- Columbia Laboratories, Inc.
WHITEHOUSE STATION, N.J., Sept. 4, 2014 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S.
ROCKLAND, Mass., Sept.
- Improves workflows and increases reliability with new ergonomic design BILLERICA, Mass., Aug.
Project Seeks to Provide Better Post-Fracture Care and Reduce the Two Million Broken Bones Caused By Osteoporosis Each Year PITTSBURGH, Aug.